Filing Details

Accession Number:
0001225208-11-012585
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-04-29 17:06:56
Reporting Period:
2011-04-28
Filing Date:
2011-04-29
Accepted Time:
2011-04-29 16:06:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1385187 Covidien Plc COV Surgical & Medical Instruments & Apparatus (3841) 980624794
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1399738 G Kevin Dasilva C/O Covidien
15 Hampshire Street
Mansfield MA 02048
Vice President And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2011-04-28 8,000 $38.65 25,219 No 4 M Direct
Ordinary Shares Acquisiton 2011-04-28 3,731 $35.45 28,950 No 4 M Direct
Ordinary Shares Acquisiton 2011-04-28 2,487 $36.99 31,437 No 4 M Direct
Ordinary Shares Disposition 2011-04-28 4,721 $56.62 26,716 No 4 S Direct
Ordinary Shares Disposition 2011-04-28 14,218 $56.64 12,498 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2011-04-28 3,731 $0.00 3,731 $35.45
Ordinary Shares Stock Option (Right to Buy) Disposition 2011-04-28 8,000 $0.00 8,000 $38.65
Ordinary Shares Stock Option (Right to Buy) Disposition 2011-04-28 2,487 $0.00 2,487 $36.99
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2014-03-25 No 4 M Direct
8,463 2016-11-20 No 4 M Direct
0 2015-11-21 No 4 M Direct
Footnotes
  1. The price reported is the weighted average price. Shares were sold in multiple transactions at prices ranging from $56.61 to $56.64. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares sold at each price.
  2. Fully exercisable.